A generative model does not know what it does not know. When it proposes a molecule, a binding pose, or a mechanism, the practical question, for anyone reading its output or underwriting the platform that produced it, is whether the answer is real or a confident fiction.

The week in numbers Disclosed cash and committed capital first. The milestone-inclusive "up to" ceilings are noted second, not led with: where an upfront or a committed amount is disclosed, that is the number to anchor on. * $1.55B upfront cash: Servier to Edgewise for the muscular dystrophy

A royalty stream is only as good as the documents that prove it. The data room is where a buyer decides whether the cashflow it is being shown is real, durable, transferable, and unencumbered. Get the room right and a deal closes in weeks. Get it wrong and the buyer

Retro Biosciences is a San Francisco-based longevity biotech founded in 2021 with a $180 million seed round funded entirely by OpenAI CEO Sam Altman, pursuing cellular reprogramming, autophagy, and cell replacement to add ten healthy years to the human lifespan.

What is M Ventures? M Ventures is the strategic corporate venture capital arm of Merck KGaA, Darmstadt, Germany, the German science and technology group with operations spanning pharmaceuticals, life science tools and bioprocessing, and electronics materials. Founded in 2009 with an initial focus on healthcare drug development, M Ventures has

Why non-dilutive capital sometimes cuts against the stock Royalty monetisation is sold as the friendliest capital a biotech can raise. Most of the time, the market agrees. The interesting question is the exception: the deals where a non-dilutive, roughly value-neutral transaction takes a fifth of the equity off in a

Two things in pharmaceutical finance carry the name of the same Swiss city, and they are starting to collide. The first Basel is the one this newsletter follows. It is the city on the Rhine where Roche and Novartis turn chemistry into product, where the monoclonal antibody was first made,

Insurance once sat at the center of pharmaceutical royalty finance. The two foundational securitizations of the asset class both relied on a third-party guarantor standing behind the notes: BioPharma Royalty Trust I in 2000 and Royalty Pharma Finance Trust in 2003. In the 2003 deal, the guarantor was the rating.

The week in numbers Disclosed cash and committed capital first. The milestone-inclusive "up to" ceilings are noted second, not led with: where an upfront or a committed amount is disclosed, that is the number to anchor on. * $650M upfront: Pfizer to Innovent on signing of the global oncology